一項最新研究報道瑞帕霉素釋放支架植入手術(shù)，用于治療那些接受過金屬支架治療又發(fā)生再狹窄的患者，是十分安全有效的。

意大利San Donato醫(yī)院(Arezzo, Italy)評估了瑞帕霉素釋放支架植入手術(shù)患者的成功率，共計244例患者未經(jīng)選擇的首次支架植入之后，在原來冠狀動脈或者隱靜脈移植發(fā)生再狹窄(ISR)，被入選了TRUE臨床研究。

瑞帕霉素支架被成功植入了病變區(qū)域。在9個月的隨訪中，4例患者(1.6%)死亡，4例出現(xiàn)心肌梗塞(MI)。缺血驅(qū)動的目標(biāo)血管再形成(TVR)見于12例患者(4.9%)，而總體無事件生存的患者有227例(93%)。盡管9個月的隨訪中計劃對所有患者進(jìn)行血管造影檢查，只有150例(62%)患者完成了檢查，在這些患者中有13例(8.7%)發(fā)生了再狹窄。
 
Sirolimus Stent Safe for Restenosis Patients
 
A new study reports that sirolimus-eluting stent implantation appears to be safe and effective in restenosis patients originally treated with bare metal stents.

Researchers at San Donato Hospital (Arezzo, Italy) evaluated the success of implanting sirolimus-eluting stents in 244 unselected patients with first-time in-stent restenosis (ISR) in a native coronary artery or saphenous vein graft, who were enrolled in the Tuscany Registry of sirolimus for Unselected in-stent restenosis (TRUE) study.

The sirolimus stents were successfully implanted in all lesions. At nine-month follow-up, four patients (1.6%) had died and four had a myocardial infarction (MI). Ischemia-driven target vessel revascularization (TVR) was seen in 12 patients (4.9%), for a cumulative event-free survival of 227 patients (93%). Although nine-month follow-up angiography was planned in all patients, only 150 (62%) patients completed it, and restenosis was present in 13 (8.7%) of these patients.